ClinicalTrials.gg
RecruitingNCT06514534ASC4TARGETUpdated Apr 21, 2026

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

A Phase 2 interventional study of ABL001/Asciminib in Chronic Myeloid Leukemia (CML), sponsored by Novartis Pharmaceuticals. Recruiting at 6 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Planned enrollment
19th of 21
20 · median 100
Started
2025
with 1 other
Phase 2
11 of 21
6 open now
Primary completion
2029-02
later than 6 of 12 live
Registered
19th of 21
by date
Lead sponsor
12 of 21
Novartis Pharmaceuticals

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 19th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 6 of the 12 other live ones, and was the 19th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect additional data on the effectiveness and safety of asciminib for these patients. By determining the drug's capacity to manage the disease and enhance patients outcomes, the study is designed to fill the unmet medical need and potentially offer a new therapeutic path for patients at a treatment deadlock.

Read the detailed description

This study is a Phase II, multi-center, single-arm prospective, open-label study that aims to evaluate the efficacy and safety of oral asciminib in patients with CML-CP or CML-AP with T315I mutation and after at least one tyrosine kinase inhibitors (TKI) and are resistant, intolerant, or ineligible for treatment with ponatinib.

Patients who have not been previously treated with asciminib would be enrolled in this study. The researchers will assess the effectiveness of asciminib in these participants, as well as evaluate its safety profile. The study will consist of two phases:

  • The "core phase" which aims to answer the scientific and medical objectives.
  • An "extension phase" intended to provide opportunity to the participants to continue their ongoing treatment (asciminib) up to commercialization in France or decision to not commercialize asciminib for the study population (stopping development, refusal to extend marketing authorization, refusal of reimbursement).
03

Conditions studied

  • Chronic Myeloid Leukemia (CML)

Keywords

  • Asciminib
  • ABL001
  • Abelson proto-oncogene (ABL1)
  • Chronic Myelogenous Leukemia (CML)
  • BCR::ABL1
  • Phase II
  • Tyrosine kinase inhibitor (TKI)
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Male or female participants with a diagnosis of CML-CP or CML-AP ≥ 18 years of age.
  • Patients with CML-CP or CML-AP with history of documented T315I mutation after at least one TKI and are resistant, intolerant, or ineligible to ponatinib (according to Investigator judgment)
  • Not already treated with asciminib or another any allosteric TKI
  • Failure (adapted from the 2020 \& 2013 ELN Guidelines) or intolerance to Ponatinib at the time of Screening.
  • Ineligible to ponatinib according to Investigator (based on EU ponatinib SmPC)
  • Evidence of typical BCR::ABL1 transcript or atypical transcripts at the time of Screening which are amenable to standardized or non-standardized RQ-PCR quantification.

Exclusion criteria

Exclusion Criteria:

  • Previous hematopoietic stem-cell transplantation
  • Cardiac or cardiac repolarization abnormality
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension)
  • History of clinical acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis (except if ponatinib-induced and completely resolved at time of Screening)
  • History of acute or chronic liver disease (i.e., cirrhosis; liver impairment)
  • Known presence of significant congenital or acquired bleeding disorder unrelated to cancer
  • History of other active within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
  • Known history of (HIV), chronic Virus (HBV), or chronic Virus (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) and Hepatitis B core antibody (HBcAb / anti HBc) will be performed at Screening
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • Treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with study treatment:

    • Moderate or strong inducers of
    • Moderate or strong inhibitors of CYP3A
  • Pregnant or nursing (lactating) women
  • Women of
  • Compound mutant T315I resistant to asciminib monotherapy (polyclonal ABL1 mutations including T315I can be enrolled) Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Asciminib (Scemblix®)

    Asciminib will be administered 200 mg twice a day orally. The minimum dose is 200 mg, and maximum dose is 400 mg.

    Drug: ABL001/Asciminib

Interventions

  • DrugABL001/Asciminib

    Drug page: Asciminib

    The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition. The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID). The drug will be administered orally, allowing for convenient and non-invasive administration.

06

What researchers measure

Primary outcomes

  1. Rate of BCR::ABL1 (Breakpoint Cluster Region Gene::Abelson proto-oncogene) IS (International Scale) ≤ 1% [MR2 (Molecular Response 2)]

    Evaluation of asciminib efficacy : proportion of patients with MR2 (BCR::ABL1 IS ≤1%) level of response at 12 months.

    Time frame: Month 12

Secondary outcomes

  1. Kinetics of response: BCR::ABL1 IS (MR2, MMR, MR4.0, MR4.5, undetectable MR4.5)

    Proportion of patients achieving the response levels (MR2, MMR, MR4.0, MR4.5, undetectable MR4.5)

    Time frame: At 3, 6, 9, 12, 18 and 24 months

  2. Estimate response to treatment MR2 at 12 months in participants with BCR::ABL1 IS > 1% at treatment initiation or maintenance of MR2 at 12 months in participants with MR2 at treatment initiation

    Proportion of patients with MR2 level of response (BCR::ABL1 IS ≤ 1%) in participants without MR2 at treatment initiation or maintenance of MR2 at 12 months in participants with MR2 at treatment initiation.

    Time frame: At 12 months

  3. Time to Major Molecular Response (MMR) (for participants not in MMR at treatment initiation)

    Major Molecular Response (MMR) criteria is defined as a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to the standardized Baseline equivalent to ≤ 0.1 % BCR::ABL1 % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

    Time frame: up to 24 months

  4. Duration of MMR

    MMR criteria is defined as a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to the standardized Baseline equivalent to ≤ 0.1 % BCR::ABL1 % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

    Time frame: up to 24 months

  5. Time to Molecular Response 2 (MR2) (for participants not in MR2 at treatment initiation)

    MR2 criteria is defined as a ≥ 2.0 log reduction in BCR::ABL1 transcripts compared to the standardized Baseline equivalent to ≤ 1 % BCR::ABL1 % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.

    Time frame: up to 24 months

  6. Duration of MR2

    MR2 criteria is defined as a ≥ 2.0 log reduction in BCR::ABL1 transcripts compared to the standardized Baseline equivalent to ≤ 1 % BCR::ABL1 % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample

    Time frame: up to 24 months

  7. Overall survival (OS)

    Overall Survival (OS) is defined as the time from the first dose of study medication to death due to any cause. If a patient is not known to have died, then OS will be censored at the latest date the patient was known to be alive (on or before the cut-off date).

    Time frame: up to 24 months

  8. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as time from the first dose of study medication to earliest occurrence of documented disease progression to AP/BC (depending on CML phase at asciminib initiation: CP or AP) or death due to any cause, whichever occurs first.

    Time frame: up to 24 months

  9. Event Free Survival (EFS)

    Event Free Survival is defined as time from the first dose of study medication to an event which may include: * Treatment failure * Confirmed loss of MR2 at any time while on study treatment, * Discontinuation of study treatment due to AE, * Progression to AP/BC (including progressions observed during the survival follow up period), * Death from any cause (including deaths observed during the survival follow-up period).

    Time frame: up to 24 months

  10. Failure Free Survival (FFS)

    Failure Free Survival (FFS) is defined as time from the first dose of study medication to a failure event which may include: * Treatment failure * Confirmed loss of MR2 at any time while on study treatment, * Discontinuation of study treatment due to AE.

    Time frame: up to 24 months

  11. Adverse events (AEs) and Serious Adverse events (SAEs)

    Description/severity (grade of severity) of AE (all AE, serious or not serious AE, related and not related AE), and number of patients who discontinued the treatment due to AE.

    Time frame: up to 24 months

  12. Deaths and reasons for death

    To evaluate the safety and tolerability profile of asciminib.

    Time frame: up to 24 months

07

Study locations

6 of 6 sites recruiting
  • Novartis Investigative Site
    Bordeaux, 33076, France
    Recruiting
  • Novartis Investigative Site
    Lille, 59037, France
    Recruiting
  • Novartis Investigative Site
    Lyon, 69373, France
    Recruiting
  • Novartis Investigative Site
    Nantes, 44093, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75475, France
    Recruiting
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2029, 47 months after the start.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's planned 47 months is close to that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Feb 18, 2025
Primary completionEst.
Feb 17, 2029
CompletionEst.
Feb 18, 2029
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06514534
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Feb 18, 2025
Primary completion
Feb 17, 2029 (estimated)
Completion
Feb 18, 2029 (estimated)
Last update
Apr 21, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion